Medicare Expands Coverage for NeoGenomics RaDaR ST Assay to Include Immunotherapy Monitoring
Medicare has expanded coverage for NeoGenomics’ RaDaR ST MRD assay to include monitoring immunotherapy response in patients with late-stage solid tumors.
Category: Company News
Company News
Latest
Company News
Latest
BRAINBox Solutions Secures Funding for Point-of-Care Concussion Testing
BRAINBox Solutions has secured financing from Pivotal Capital Partners and New Horizon Bank to advance its point-of-care and lab-based concussion diagnostic devices for traumatic brain injury.
Company News
Latest
Lucid Diagnostics Secures Commercial Coverage Policy for Its Esophageal DNA Test
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
10x Genomics and Lausanne University Hospital Collaborate on Cancer Diagnostic Research
10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.
Read More
YD Bio Launches Cross-Border Cancer Testing Pilot in Canada
YD Bio and Numia Health have launched a six-month pilot in British Columbia to evaluate cross-border blood-based cancer testing, supporting up to 50 patient episodes with laboratory analysis performed at a CLIA-certified U.S. facility.
Read More
Healthcare Executives Signal Growing Strategic Value of Laboratory Services
A Siemens Healthineers–commissioned survey found 82% of healthcare executives considered expanding lab services, with modernization and AI upgrades seen as top priorities for supporting organizational goals.
Read More
IRIS Kinetics Unveils Point-of-Care Kinetic Biosensing Platform
The IRIS TX-100 uses cartridge-based technology to measure up to 100 biomarkers in approximately 10 minutes.
Read More
Pictor Unveils High-Resolution Protein Analysis Platform at ADLM 2026
The research-use-only platform combines imaging, software, and multiplex protein analysis into a standard 96-well workflow designed to simplify biomarker research.
Read More
Revvity Developing Automated Platform for Tuberculosis Testing
Revvity is developing the T-SPOT A201, an automated platform for latent tuberculosis testing in high-volume labs, with planned launch in 2027 pending regulatory approval.
Read More
Alamar Gains Rights to Develop Clinical Alzheimer’s Blood Tests Using ALZpath Antibody
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
Read More
Countable Labs Launches Program Connecting Researchers With Single-Molecule PCR Services
The program connects researchers with certified laboratories offering single-molecule PCR testing, technical support, and bioinformatics expertise.
Read More
NanoSomiX and Beckman Coulter Partner to Develop Blood Tests for Brain Diseases
NanoSomiX and Beckman Coulter Diagnostics have partnered to develop automated blood-based immunoassays for detecting neurodegenerative disease biomarkers, aiming to enable scalable testing in clinical and research laboratories.
Read More
ARUP Laboratories Launches Spectral Flow Cytometry Test for Multiple Myeloma Monitoring
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
Read More
Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Read More
Labcorp to Pay $14.5 Million to Settle Allegations of Unnecessary Urine Drug Testing
Labcorp will pay $14.5 million to settle DOJ allegations it billed Medicare for medically unnecessary urine drug tests by submitting claims for both presumptive and definitive testing on the same sample between 2018 and 2023.
Read More
CareDx Completes Acquisition of Cancer Diagnostic Company
The deal adds a blood-based test for viral-mediated cancers to the company’s portfolio of transplant and cell therapy services.
Read More
Anthem to Cover Quanterix’s LucentAD Complete Alzheimer’s Blood Test
The insurer will provide coverage for the multi-analyte test starting July 2026, following new data showing parity with mass spectrometry.
Read More
Anthem Establishes Coverage of C2N Diagnostics’ Blood Test for Alzheimer’s Disease Evaluation
Anthem Blue Cross and Blue Shield will cover C2N Diagnostics’ PrecivityAD2 blood test for Alzheimer’s disease evaluation starting Oct 1, 2026, expanding access to the diagnostic tool for adults with cognitive decline.
Read More